Background: The immunogenicity of COVID-19 vaccine among patients receiving anti-CD20 monoclonal antibody (Ab) treatment has not been fully investigated. Detectable levels of SARS-CoV-2 immunoglobulin G (IgG) are believed to have a predictive value for immune protection against COVID-19 and is currently a surrogate indicator for vaccine efficacy. Objective: To determine IgG Abs in anti-CD20 treated patients with multiple sclerosis (MS). Method: IgG Abs against SARS-CoV-2 spike receptor–binding domain were measured with the SARS-CoV-2 IgG II Quant assay (Abbott Laboratories) before and after vaccination (n = 60). Results: 36.7% of patients mounted a positive SARS-CoV-2 spike Ab response after the second dose of vaccine. Five patients (8.3%) developed Abs >264 BAU/mL, another 12 patients (20%) developed intermediate Abs between 54 BAU/mL and 264 BAU/mL and five patients (8.3%) had low levels <54 BAU/mL. Of all seropositive patients, 63.6% converted from seronegative to seropositive after the 2nd vaccine. Conclusion: Our study demonstrates decreased humoral response after BNT162b2 mRNA SARS-CoV-2 vaccine in MS patients receiving B-cell depleting therapy. Clinicians should advise patients treated with anti-CD20 to avoid exposure to SARS-CoV-2. Future studies should investigate the implications of a third booster vaccine in patients with low or absent Abs after vaccination.
|Tidsskrift||Multiple Sclerosis and Related Disorders|
|Status||Udgivet - nov. 2021|
Bibliografisk noteFunding Information:
We acknowledge the great help received from patients participating in this trial and our team of technicians and study coordinators represented by Gunhild Brixen (Sormani et al. 2021) Nielsen, Rikke Bjerre Rosengren (Sormani et al. 2021) and Pia Hannesbo (Khoury et al. 2021). We acknowledge grants given by the Lundbeck Neurological Scholarship delegated by Danish Neurological Society and by Region of Southern Denmark.
T Sejbaek has received travel grants from Biogen, Merck, Novartis and Roche, has received research grants from Biogen and has served on advisory boards for Biogen and Novartis.
M Wilson has received research grant funding from Roche/Genentech and speaking honoraria from Novartis, Takeda and Genentech.